Vaderis Therapeutics
Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia
$152MSeries B
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia
Develops treatments for patients suffering from thromboembolic disease
Provides in-network psychiatric care using AI-powered technology